Literature DB >> 21847537

Use of lithium in the treatment of bipolar disorder in late-life.

Ramsey D'Souza1, Tarek K Rajji, Benoit H Mulsant, Bruce G Pollock.   

Abstract

Lithium is the oldest and still one of the most frequently prescribed mood stabilizers in the treatment of bipolar disorder. Nonetheless, the evidence for lithium efficacy in older patients with bipolar disorder is almost entirely extrapolated from younger adult patients. Here we review the literature on lithium in older patients with bipolar disorder, concentrating on the past 3 years. A definitive study demonstrating the efficacy and safety of lithium in older patients with bipolar disorder is still missing. However, several lines of indirect evidence suggest that it is beneficial and advantageous over other mood stabilizers in the acute and maintenance treatment of late-life bipolar disorder. In addition, lithium may have unique properties as a regenerative therapeutic with specific benefits in reducing the cognitive impairment and suicide rates associated with bipolar disorder across the adult lifespan. Aging-associated pharmacokinetic and pharmacodynamic changes as well as increased rates of medical comorbidities and polypharmacy predispose older patients to a higher risk of lithium toxicity. Careful monitoring and adjustment of lithium dosage is especially important in older adults to minimize the risk of toxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21847537     DOI: 10.1007/s11920-011-0228-9

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  51 in total

1.  Mental health service use by elderly patients with bipolar disorder and unipolar major depression.

Authors:  S J Bartels; B Forester; K M Miles; T Joyce
Journal:  Am J Geriatr Psychiatry       Date:  2000       Impact factor: 4.105

Review 2.  The critical role of clinical pharmacology in geriatric psychopharmacology.

Authors:  Bg Pollock; Ce Forsyth; Rr Bies
Journal:  Clin Pharmacol Ther       Date:  2008-11-26       Impact factor: 6.875

3.  Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death.

Authors:  Elisabetta Patorno; Rhonda L Bohn; Peter M Wahl; Jerry Avorn; Amanda R Patrick; Jun Liu; Sebastian Schneeweiss
Journal:  JAMA       Date:  2010-04-14       Impact factor: 56.272

4.  Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder.

Authors:  Robert D Gibbons; Kwan Hur; C Hendricks Brown; J John Mann
Journal:  Arch Gen Psychiatry       Date:  2009-12

Review 5.  Managing bipolar disorder in the elderly: defining the role of the newer agents.

Authors:  Martha Sajatovic; Subramoniam Madhusoodanan; Nicoleta Coconcea
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  Lithium for older adults with bipolar disorder: Should it still be considered a first-line agent?

Authors:  Kenneth I Shulman
Journal:  Drugs Aging       Date:  2010-08-01       Impact factor: 3.923

7.  Medical comorbidity and health-related quality of life in bipolar disorder across the adult age span.

Authors:  Howard H Fenn; Mark S Bauer; Lori Altshuler; Lori Alshuler; Denise R Evans; William O Williford; Amy M Kilbourne; Thomas P Beresford; Gail Kirk; Margaret Stedman; Louis Fiore
Journal:  J Affect Disord       Date:  2005-05       Impact factor: 4.839

8.  Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?

Authors:  G J Moore; J M Bebchuk; K Hasanat; G Chen; N Seraji-Bozorgzad; I B Wilds; M W Faulk; S Koch; D A Glitz; L Jolkovsky; H K Manji
Journal:  Biol Psychiatry       Date:  2000-07-01       Impact factor: 13.382

9.  Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease.

Authors:  Thomas Leyhe; Gerhard W Eschweiler; Elke Stransky; Thomas Gasser; Peter Annas; Hans Basun; Christoph Laske
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  Divalproex, lithium and suicide among Medicaid patients with bipolar disorder.

Authors:  Jon C Collins; Bentson H McFarland
Journal:  J Affect Disord       Date:  2007-08-16       Impact factor: 4.839

View more
  8 in total

Review 1.  Lithium Toxicity in Older Adults: a Systematic Review of Case Reports.

Authors:  Meng Sun; Nathan Herrmann; Kenneth I Shulman
Journal:  Clin Drug Investig       Date:  2018-03       Impact factor: 2.859

2.  Current electroconvulsive therapy practice and research in the geriatric population.

Authors:  Nancy Kerner; Joan Prudic
Journal:  Neuropsychiatry (London)       Date:  2014-02

Review 3.  Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.

Authors:  Chi-Tso Chiu; Zhifei Wang; Joshua G Hunsberger; De-Maw Chuang
Journal:  Pharmacol Rev       Date:  2013-01-08       Impact factor: 25.468

4.  Prophylaxis and treatment of bipolar disorder in older adults.

Authors:  Charlotte L Allan; Klaus P Ebmeier
Journal:  J Psychiatry Neurosci       Date:  2012-07       Impact factor: 6.186

5.  The combination effects of licl and the active leflunomide metabolite, A771726, on viral-induced interleukin 6 production and EV-A71 replication.

Authors:  Hui-Chen Hung; Shin-Ru Shih; Teng-Yuan Chang; Ming-Yu Fang; John T-A Hsu
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

Review 6.  Mood disorders in the elderly: prevalence, functional impact, and management challenges.

Authors:  Leandro da Costa Lane Valiengo; Florindo Stella; Orestes Vicente Forlenza
Journal:  Neuropsychiatr Dis Treat       Date:  2016-08-24       Impact factor: 2.570

7.  Lithium chloride inhibits early stages of foot-and-mouth disease virus (FMDV) replication in vitro.

Authors:  Fu-Rong Zhao; Yin-Li Xie; Ze-Zhong Liu; Jun-Jun Shao; Shi-Fang Li; Yong-Guang Zhang; Hui-Yun Chang
Journal:  J Med Virol       Date:  2017-08-28       Impact factor: 2.327

8.  Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement.

Authors:  Lingling Hou; Nian Xiong; Ling Liu; Jinsha Huang; Chao Han; Guoxin Zhang; Jie Li; Xiaoyun Xu; Zhicheng Lin; Tao Wang
Journal:  BMC Neurosci       Date:  2015-11-25       Impact factor: 3.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.